Your session is about to expire
← Back to Search
PD-L1 Inhibitor
Durvalumab and focal radiotherapy for Ovarian Cancer
Phase 1
Waitlist Available
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year
Awards & highlights
Summary
It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation therapy given with durvalumab.
Eligible Conditions
- Ovarian Cancer
- Peritoneal Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Determine the maximum tolerated dose of durvalumab combined with focal irradiation for use in recurrent ovarian cancer
Secondary study objectives
CA-125 response rate
Immune-related response rate
Objective response rate
Other study objectives
Survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: Durvalumab and focal radiotherapyExperimental Treatment2 Interventions
Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Focal radiotherapy
1999
Completed Phase 3
~320
Durvalumab
FDA approved
Find a Location
Who is running the clinical trial?
British Columbia Cancer AgencyLead Sponsor
172 Previous Clinical Trials
90,582 Total Patients Enrolled
5 Trials studying Ovarian Cancer
349 Patients Enrolled for Ovarian Cancer
Ozmosis Research Inc.Industry Sponsor
21 Previous Clinical Trials
5,029 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger